NK
Nkarta, Inc.
NKTX · NASDAQ
$2.95 +1.37% (+$0.04)
1M +11.20%
Market Cap $211.1M
P/E Ratio -
Div. Yield -
ROE 39.64%
Bulios Fair Price
$3.02
2.4% upside
Current Price
$2.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NKTX is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.85x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 5.68%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 41.15%
ROE 39.64%
ROA 34.75%
Debt
100 /100
Low Debt/Equity 0.30x
Current ratio 7.98x
Int. coverage N/A
Stability
76 /100
Stable Beta 0.98x
EPS volatility 13.63%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NKTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul J. Hastings
Employees
106
Headquarters
South San Francisco
Upcoming events
10 NOV
Earnings
Upcoming earnings report